Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 8
2020 20
2021 29
2022 28
2023 25
2024 40

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Powles T, et al. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. N Engl J Med. 2021. PMID: 33577729 Free PMC article. Clinical Trial.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Koshkin VS, et al. Cancer. 2022 Mar 15;128(6):1194-1205. doi: 10.1002/cncr.34057. Epub 2021 Dec 9. Cancer. 2022. PMID: 34882781 Free article.
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. Chou J, et al. Eur Urol Oncol. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23. Eur Urol Oncol. 2022. PMID: 35216942 Free PMC article.
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm.
Ingen-Housz-Oro S, Elshot YS, Segura S, Marchand A, Pouessel D, Kluger N, de Barros Silva G, Ortiz-Brugues A, Aubert M, Saldana C, Mavroudis D, Burle E, Tournier E, Koumaki D, Sibaud V. Ingen-Housz-Oro S, et al. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e99-e101. doi: 10.1111/jdv.19454. Epub 2023 Aug 29. J Eur Acad Dermatol Venereol. 2024. PMID: 37607297 No abstract available.
Drug extravasation with Enfortumab vedotin.
Grant CR, de Kouchkovsky D, Kalebasty AR, Mar N. Grant CR, et al. J Oncol Pharm Pract. 2023 Oct;29(7):1789-1792. doi: 10.1177/10781552231185505. Epub 2023 Jul 4. J Oncol Pharm Pract. 2023. PMID: 37401244 Free PMC article.
127 results